News | December 22, 2011

Abbott Initiates Trial for Drug-Eluting Bioresorbable Peripheral Stent

December 22, 2011 ­– Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries. It will specifically target blockages that resulted in claudication (leg pain upon walking).

Claudication is the most common symptom in patients with peripheral artery disease (PAD), and is associated with diminished physical activity and poor quality of life for patients. The SFA and iliac arteries, located in the upper leg and pelvis, are common areas of blockage in patients with PAD. The first patient was treated with an Esprit BVS as part of the trial by Marc Bosiers, M.D., head of the Department of Vascular Surgery at St. Blasius Hospital in Dendermonde, Belgium.

The Esprit drug-eluting BVS is designed specifically for use in peripheral arteries and is made of polylactide, the same proven biocompatible material used in the company's Absorb drug-eluting BVS for coronary artery disease. Absorb is authorized for sale in Europe and is investigational in the United States. Esprit is designed to restore blood flow by opening a blocked vessel and providing support until it is healed. Once the vessel can remain open without the extra support, the scaffold is designed to dissolve, leaving the vessel free of a permanent metallic implant. Because a permanent implant is not left behind, clinical outcomes may be improved and options for retreatment of the vessel preserved.

"Treating blockages in the SFA is a clinical challenge, as there are unique biomechanical forces exerted on the SFA during normal leg movement, which can lead to restenosis or re-narrowing of the vessel," said Johannes Lammer, M.D., professor of radiology at the Medical University of Vienna, Austria, and principal investigator for the ESPRIT I trial. "Current endovascular therapies, such as self-expanding stents and angioplasty balloons, have limitations and have not solved the problem of restenosis. A bioresorbable drug eluting device, designed to act as a temporary scaffold to support the vessel and then fully dissolve, may change the way we treat peripheral artery disease."

The ESPRIT I trial is a single-arm, multi-center trial designed to evaluate the safety and performance of the Esprit therapy in approximately 30 patients with claudication resulting from PAD of the SFA or iliac arteries. Up to 10 clinical trial sites in Europe will participate in the trial. Patients will undergo clinical hemodynamic (blood movement), functional and quality-of-life follow-up at one, six and 12 months and at two and three years following the procedure.

"ESPRIT I is the first clinical trial to evaluate our bioresorbable technology in patients with disease in the SFA and iliac arteries," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "In addition to ESPRIT I, we also are investigating our bioresorbable therapy for the treatment of below-the-knee critical limb ischemia – a severe form of PAD – in the ABSORB BTK trial. We've seen promising long-term clinical data with our bioresorbable therapy in coronary patients, and we believe there is potential for this technology in the treatment of PAD."

The Esprit uses the same polymer and drug (everolimus) as the Absorb BVS, but has a novel stent design and comes in larger diameters and longer lengths. Esprit is currently investigational and is not available for sale.

ABSORB BTK Trial

Abbot also has the ongoing ABSORB BTK trial evaluating the safety and efficacy of Absorb for the treatment of below-the-knee (BTK) critical limb ischemia. Critical limb ischemia is a severe form of PAD that occurs when blocked vessels impair blood flow to the lower extremities, which can eventually lead to limb amputation. Abbott announced the initiation of the trial in September 2011.

Absorb has received CE mark and is authorized for sale in Europe for the treatment of coronary artery disease. In the U.S., Absorb currently is investigational and is not available for sale.

For more information: www.abbott.com

 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init